Σιγκαπούρη - Αγγλικά - HSA (Health Sciences Authority)

m.b.d. marketing (s) pte ltd - dobutamine hcl eqv dobutamine - injection - 50.0mg - dobutamine hcl eqv dobutamine 50 mg/ml

Ηνωμένες Πολιτείες - Αγγλικά - NLM (National Library of Medicine)

hf acquisition co llc, dba healthfirst - dobutamine hydrochloride (unii: 0wr771djxv) (dobutamine - unii:3s12j47372) - dobutamine hydrochloride in 5% dextrose injection is indicated when parenteral therapy is necessary for inotropic support in the short-term treatment of patients with cardiac decompensation due to depressed contractility resulting either from organic heart disease or from cardiac surgical procedures. experience with intravenous dobutamine in controlled trials does not extend beyond 48 hours of repeated boluses and/or continuous infusions. whether given orally, continuously intravenously, or intermittently intravenously, neither dobutamine nor any other cyclic-amp-dependent inotrope has been shown in controlled trials to be safe or effective in the long-term treatment of congestive heart failure. in controlled trials of chronic oral therapy with various such agents, symptoms were not consistently alleviated, and the cyclic-amp-dependent inotropes were consistently associated with increased risks of hospitalization and death. patients with nyha class iv symptoms appeared to be at particular risk. dobutamine hydrochloride in 5% dextrose injection is contraindicated in patients with idiopathic hypertrophic subaortic stenosis and in patients who have shown previous manifestations of hypersensitivity to dobutamine. solutions containing dextrose may be contraindicated in patients with known allergy to corn or corn products.

Αυστραλία - Αγγλικά - Department of Health (Therapeutic Goods Administration)

hospira australia pty ltd - dobutamine hydrochloride -

Αυστραλία - Αγγλικά - Department of Health (Therapeutic Goods Administration)

pfizer australia pty ltd - sodium bicarbonate, quantity: 8.4 g - injection, intravenous infusion - excipient ingredients: disodium edetate; water for injections - 1. metabolic acidosis in severe renal disease, uncontrolled diabetes, circulatory insufficiency due to shock or severe dehydration, extracorporeal circulation of blood, cardiac arrest and severe primary lactic acidosis where a rapid increase in plasma total co2 content is crucial. treatment of metabolic acidosis should be concurrent with measures designed to control the cause of the acidosis. 2.urinary alkalinisation in the treatment of certain drug intoxications (ie barbiturates, salicylates, lithium, methyl alcohol) and in the haemolytic reactions requiring alkalinisation of the urine to diminish nephrotoxicity of blood pigments. urinary alkalinisation is also used in methotrexate therapy to prevent nephrotoxicity. 3.severe diarrhoea which is often accompanied by a significant loss of bicarbonate.

Αυστραλία - Αγγλικά - Department of Health (Therapeutic Goods Administration)

merck sharp & dohme (australia) pty ltd - posaconazole, quantity: 300 mg - injection, concentrated - excipient ingredients: sulfobutyl betadex sodium; disodium edetate; hydrochloric acid; sodium hydroxide; water for injections - noxafil (posaconazole) concentrated injection is indicated for use in the treatment of the following invasive fungal infections in adults: invasive aspergillosis in patients intolerant of, or with disease that is refractory to, alternative therapy. fusariosis, zygomycosis, coccidioidomycosis, chromoblastomycosis, and mycetoma in patients intolerant of, or with disease that is refractory to, alternative therapy. noxafil is also indicated for the: prophylaxis of invasive fungal infections among adults, who are at high risk of developing these infections, such as patients with prolonged neutropenia or haematopoietic stem cell transplant (hsct) recipients.

Ισραήλ - Αγγλικά - Ministry of Health

raz pharmaceutics ltd, israel - dobutamine as hydrochloride - concentrate for solution for infusion - dobutamine as hydrochloride 12.5 mg/ml - dobutamine - dobutamine is indicated for patients who require a positive inotropic support in the short term treatment of adults with cardiac decompensation due to depressed contractility resulting either from organic heart disease or from cardiac surgical procedures, especially when a low cardiac output is associated with raised pulmonary pressure.

Ιρλανδία - Αγγλικά - HPRA (Health Products Regulatory Authority)

pfizer healthcare ireland - dobutamine hydrochloride - concentrate for soln for inf - 12.5 mg/ml

Ιρλανδία - Αγγλικά - HPRA (Health Products Regulatory Authority)

hameln pharmaceuticals gmbh - dobutamine hydrochloride - concentrate for soln for inf - 12.5 mg/ml

Ιρλανδία - Αγγλικά - HPRA (Health Products Regulatory Authority)

hameln pharmaceuticals gmbh - dobutamine hydrochloride - concentrate for soln for inf - 50 mg/ml

Αυστραλία - Αγγλικά - Department of Health (Therapeutic Goods Administration)

sandoz pty ltd - dobutamine hydrochloride -